Bitam, Sara
Elbahnsi, Ahmad
Creste, Geordie
Pranke, Iwona
Chevalier, Benoit
Berhal, Farouk
Hoffmann, Brice
Servel, Nathalie
Baatalah, Nesrine
Tondelier, Danielle
Hatton, Aurelie
Moquereau, Christelle
Faria Da Cunha, Mélanie
Pastor, Alexandra
Lepissier, Agathe
Hinzpeter, Alexandre
Mornon, Jean-Paul
Prestat, Guillaume
Edelman, Aleksander
Callebaut, Isabelle
Gravier-Pelletier, Christine
Sermet-Gaudelus, Isabelle
Funding for this research was provided by:
Vaincre La Mucoviscidose (RF20180502264)
Agence Nationale de la Recherche (ANR-13-BSV1-0019-02)
GENCI-[CINES] (2017-A0020707206, 2018-A0040707206, 2019-A006707206)
Article History
Received: 15 December 2019
Accepted: 18 January 2021
First Online: 25 March 2021
Change Date: 15 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-021-98301-4
Competing interests
: SB, AE, CG, IP, ¨BC, FB, BH, NS, DT, AH, CM, MFDC, AL, AHi, JPM, GP, AE, IC, CGP, do not declare any potential financial and non-financial competing interest. ISG declares following fundings from Vertex Pharmaceuticals: Innovation Award funding program 2016 and 2017. She was PI in clinical trials from Vertex Pharmaceuticals and took part to scientific advisory boards organized by Vertex Pharmaceuticals, Eloxx and Proteostasis.